A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

CNBC’s Deirdre Bosa, Big Technology’s Alex Kantrowitz and Wealth Enhancement’s Ayako Yoshioka, join 'Closing Bell' to discuss ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer ...

There is growing enthusiasm about China’s potential to speed up drug development with AI. And companies outside the country ...

Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...

The discovery and development of drugs in pharmacological research – including the risk assessment of active substances in ...

Precise calculations of binding free energy are pivotal in reducing the high costs and inefficiencies of drug discovery. A ...

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Makers of drugs and medical devices say the tariffs on goods from Canada, Mexico and China could have an outsized impact on ...